FMCSX Mutual Fund Forecast & Price Targets

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FMCSX Analyst Rating

Moderate Buy

158 Buy

15 Hold

1 Sell

Based on the consensus analyst ratings on 174 stocks held in FMCSX.

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FMCSX Analyst Price Target

Average Price Target

$44.59

Based on 174 Wall Street analysts offering 12 month price targets to Fidelity Mid-Cap Stock Fund holdings in the last 3 months. The average price target is $44.59 with a high forecast of $50.81 and a low forecast of $38.61. The average price target represents a 11.95% change from the last price of $39.83.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"37":"$37","44":"$44","51":"$51","40.5":"$40.5","47.5":"$47.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50.813,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.588,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$44.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.612,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.61</span>\n  </div></div>","useHTML":true}}],"tickPositions":[37,40.5,44,47.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n              \n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.05,43.64715384615384,44.24430769230769,44.84146153846154,45.43861538461538,46.03576923076923,46.63292307692308,47.23007692307692,47.827230769230766,48.42438461538462,49.02153846153846,49.618692307692314,50.21584615384616,{"y":50.813,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.05,43.16830769230769,43.28661538461538,43.404923076923076,43.523230769230764,43.64153846153846,43.759846153846155,43.87815384615384,43.99646153846154,44.114769230769234,44.23307692307692,44.35138461538462,44.469692307692306,{"y":44.588,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.05,42.708615384615385,42.367230769230765,42.02584615384615,41.684461538461534,41.34307692307692,41.00169230769231,40.66030769230769,40.31892307692308,39.977538461538465,39.636153846153846,39.294769230769234,38.953384615384614,{"y":38.612,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.45,"date":1719792000000,"info":"<div>Price: <b>$39<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":41.28,"date":1722470400000,"info":"<div>Price: <b>$41<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":41.91,"date":1725321600000,"info":"<div>Price: <b>$42<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":43.51,"date":1727740800000,"info":"<div>Price: <b>$44<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":43.14,"date":1730419200000,"info":"<div>Price: <b>$43<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":46.82,"date":1733097600000,"info":"<div>Price: <b>$47<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":42.37,"date":1735776000000,"info":"<div>Price: <b>$42<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":43.93,"date":1738540800000,"info":"<div>Price: <b>$44<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":41.38,"date":1740960000000,"info":"<div>Price: <b>$41<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":40.2,"date":1743465600000,"info":"<div>Price: <b>$40<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.85,"date":1746057600000,"info":"<div>Price: <b>$40<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":41.94,"date":1748822400000,"info":"<div>Price: <b>$42<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":43.05,"date":1751328000000,"info":"<div>Price: <b>$43<b/></div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.81

Average Price Target$44.59

Lowest Price Target$38.61

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

FMCSX Stocks With Highest Upside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

CRNX

Crinetics Pharma

9 Buy

1 Hold

0 Sell

Strong Buy

$72.67

xxxxxxxxxxxxxxxxxxxxxxxxxxx

LEGN

Legend Biotech Corporation

16 Buy

1 Hold

0 Sell

Strong Buy

$77.11

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ARGX

arGEN X

8 Buy

0 Hold

0 Sell

Strong Buy

$675.63

xxxxxxxxxxxxxxxxxxxxxxxxxxx

LFST

Lifestance Health Group, Inc.

4 Buy

1 Hold

0 Sell

Strong Buy

$8.63

xxxxxxxxxxxxxxxxxxxxxxxxxxx

RVMD

Revolution Medicines, Inc.

9 Buy

0 Hold

0 Sell

Strong Buy

$70.88

FMCSX Stocks With Highest Downside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

IBKR

Interactive Brokers Group

5 Buy

1 Hold

0 Sell

Strong Buy

$49.71

xxxxxxxxxxxxxxxxxxxxxxxxxxx

TPR

Tapestry

14 Buy

2 Hold

0 Sell

Strong Buy

$92.50

xxxxxxxxxxxxxxxxxxxxxxxxxxx

IMO

Imperial Oil

3 Buy

7 Hold

1 Sell

Hold

$103.82

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ON Semiconductor Corporation

12 Buy

15 Hold

0 Sell

Moderate Buy

$54.65

xxxxxxxxxxxxxxxxxxxxxxxxxxx

WWD

Woodward

4 Buy

3 Hold

0 Sell

Moderate Buy

$237.83

FMCSX Mutual Fund FAQ

What is FMCSX’s average 12-month price target, according to analysts?

Based on analyst ratings, Fidelity Mid-Cap Stock Fund’s 12-month average price target is 44.59.

What is FMCSX’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for FMCSX, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FMCSX a Buy, Sell or Hold?

Fidelity Mid-Cap Stock Fund has a consensus rating of Moderate Buy which is based on 158 buy ratings, 15 hold ratings and 1 sell ratings.

What is Fidelity Mid-Cap Stock Fund’s price target?

The average price target for Fidelity Mid-Cap Stock Fund is 44.59. This is based on 174 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.81 ,the lowest forecast is $38.61. The average price target represents N/A Increase from the current price of N/A.

What do analysts say about Fidelity Mid-Cap Stock Fund?

Fidelity Mid-Cap Stock Fund’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 174 Wall Streets Analysts.

How can I buy shares of FMCSX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing